66ba9b68-dcc0-4c51-a8c8-b4016502973d
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.400
- HYPOXIA+0.400
- IL6_JAK_STAT3_SIGNALING+0.400
- INFLAMMATORY_RESPONSE+0.400
- KRAS_SIGNALING_UP+0.400
- TGF_BETA_SIGNALING+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- ALLOGRAFT_REJECTION+0.300
- APOPTOSIS+0.300
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.700
- MYC_TARGETS_V2-0.600
- MYC_TARGETS_V1-0.500
- E2F_TARGETS-0.400
- FATTY_ACID_METABOLISM-0.400
- ADIPOGENESIS-0.300
- G2M_CHECKPOINT-0.300
- PANCREAS_BETA_CELLS-0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.300
- DNA_REPAIR-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03205 | — | cohortA1 | 0.878 |
| 2 | TCGA-77-8008-01A-21R-2187-07 | — | cohortSQ1 | 0.866 |
| 3 | be66e85c-d70d-4073-af6a-bcee51ef3240 | — | — | 0.861 |
| 4 | SRR17866819 | — | — | 0.859 |
| 5 | TCGA-46-3767-01A-01R-0980-07 | — | cohortSQ1 | 0.855 |
| 6 | 07234abb-aa8c-434f-898c-6f7ba28c5850 | — | — | 0.850 |
| 7 | fd618c1b-e230-408d-aed8-4ad6df3fc4e6 | — | — | 0.845 |
| 8 | 22358a97-998c-4dd2-a48c-67626c744751 | — | — | 0.843 |
| 9 | C3L-03462 | — | cohortA1 | 0.840 |
| 10 | TCGA-D6-6826-01A-11R-1915-07 | — | — | 0.839 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.400 | Remibrutinib | — uncovered |
| HYPOXIA | 0.400 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.300 | Inavolisib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.200 | Idelalisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.200 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.100 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |